Research ArticlesPlasma Concentrations of Thioridazine Metabolites and ECG Abnormalities
REFERENCES (18)
- et al.
Comp. Psychiat.
(1975) - et al.
J. Pharm. Sci.
(1976) - et al.
J. Chromatogr.
(1973) - et al.
Can. Med. Assoc. J.
(1963) - et al.
J. Am. Med. Assoc.
(1966) - et al.
Minn. Med.
(1971) - et al.
Dis. Neru. Syst.
(1971) - et al.
Curr. Ther. Res.
(1972) - et al.
J. Clin. Pharmacol.
(1974)
There are more references available in the full text version of this article.
Cited by (34)
A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia
2018, Blood AdvancesCitation Excerpt :However, it is noteworthy that following TDZ discontinuation, patient 3 continued to show significant QTc prolongation (supplemental Figure 1). Moreover, after plasma concentrations of TDZ and TDZ 5-sulfoxide (the metabolite associated with cardiotoxicity19-22) were reduced to undetectable levels, frequent QTc prolongation events continued to be noted on serial ECGs (supplemental Figure 1). These QTc changes in patient 3 were not associated with fluctuations in magnesium or potassium levels.
Stereoselective analysis of thioridazine-2-sulfoxide and thioridazine-5-sulfoxide: An investigation of rac-thioridazine biotransformation by some endophytic fungi
2008, Journal of Pharmaceutical and Biomedical AnalysisThe role of lysosomes in the cellular distribution of thioridazine and potential drug interactions
1999, Toxicology and Applied PharmacologyDetermination of the serum concentrations of thioridazine and its main metabolites using a solid-phase extraction technique and high-performance liquid chromatography
1990, Journal of Chromatography B: Biomedical Sciences and ApplicationsConvenient oxidation of phenothiazine salts to their sulfoxides with aqueous nitrous acid
1989, Journal of Pharmaceutical SciencesCardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart
1986, Toxicology and Applied Pharmacology
Copyright © 1978 Wiley-Liss, Inc., A Wiley Company. Published by Elsevier Inc. All rights reserved.